Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05841524
Other study ID # 238649
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 1, 2023
Est. completion date January 1, 2025

Study information

Verified date June 2024
Source St. Olavs Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to perform an in vivo feasibility study using real time (3D) ultrasound based vector flow imaging in 10 AAA patients (5 with intraluminal thrombus and 5 without intraluminal thrombus). Furthermore, the investigators will investigate the added value of contrast microbubbles in these high framerate, plane wave ultrasound measurements. Included patients will undergo ultrasound scanning of their AAA, using multiple ultrasound sequences. Sequences will be tested with and without the addition of ultrasound contrast microbubbles.


Description:

Currently a AAA diameter > 5.5 cm is the cut-off for treatment with the rationale that rupture risk outweighs risk of surgery at that point. Although in large cohorts such thresholds adequately reflect the repair indication, they fail in case of patient-specific decision-making. This is reflected by the fact that both small AAA rupture and large AAA's have been documented to be stable. Moreover, recently introduced biomechanical parameters show promising results with respect to improved rupture risk prediction. A key parameter is intraluminal thrombus (ILT) formation at the vessel wall, which is observed in 75% of AAA's. Recent work has shown ILT to be promoting rupture risk, outweighing its protective effect by reducing wall stress. An explanation lies in the fact that the vessel wall is primarily oxygenated due to luminal oxygen diffusion and ILT decreases oxygen supply to the AAA wall by as much as 95%. This, in turn, leads to hypoxia, inflammation and vessel wall weakening, promoting AAA rupture. Others have also shown that small AAA's (< 6 cm) that ruptured have a significantly higher volume percentage of ILT. Biomechanics behind the formation of ILT indicate that aneurysmal blood flow plays a role, in combination with the complex and patient-specific AAA geometry, inducing blood flow perturbations, e.g. vortices and stagnation zones. These local blood flow perturbations facilitate platelet adhesion and ILT formation in regions of slow and stagnant flow, in turn increasing AAA growth and the associated rupture risk. This project is a first step to quantify in vivo AAA blood flow, using high frame rate ultrasound techniques, to perform both better risk stratification and risk management. Conventional color Doppler imaging is performed using focused ultrasound beams, which limits the achievable frame rates to approximately 25 frames per second (fps). Recent developments in computer hardware and software has enabled a shift towards unfocused imaging, where anatomical ultrasound images can be made using only a single unfocused ultrasound pulse. With the new technology, the frame rate limit is suddenly increased by a factor of 500, which results in increased flexibility when designing imaging sequences. Extremely high frame rates can now be traded for increased complexity, enabling new information to be obtained. In this project, the investigators will use continuous, high frame rate, ECG gated, 3D slice acquisition to quantify blood flow at the inflow of the aneurysm. This will result in a vector flow imaging dataset, including the through plane component. The received signal is based on the in vivo scattering properties of blood. However, the technique might benefit from the addition of ultrasound contrast agents, therefore a second set of measurements will be obtained after intravenous injection of a contrast agent (SonoVue). The hypothesis is that high frame rate 3D ultrasound can be used to image aneurysm blood flow. From these measurements the investigators expect that travel distance analysis shows different outcomes between AAA patients with and without intraluminal thrombus. In turn this is another piece of the puzzle to stratify patients having a higher risk of aneurysm rupture.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 14
Est. completion date January 1, 2025
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with AAA - AAA diameter below treatment threshold of 5.5 cm Exclusion Criteria: - Hypersensitivity to the active substance(s) or any of the excipients in Sonovue - Right-to-left cardiac shunt - Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg) - Uncontrolled systemic hypertension - Severe pulmonary disease (e.g. COPD GOLD 3 or 4, adult respiratory distress syndrome) - Clinically unstable cardiac disease (recent, < 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.) - Prosthetic valves - Loss of renal function (GFR < 31 ml/min), end-stage renal disease - End-stage liver disease - Sepsis

Study Design


Intervention

Diagnostic Test:
Vector flow imaging measurement
Ultrasound measurement, using high framerate measurement techniques.

Locations

Country Name City State
Norway St. Olavs hospital, Trondheim University Hospital Trondheim Trondelag

Sponsors (3)

Lead Sponsor Collaborator
St. Olavs Hospital Norwegian University of Science and Technology, University of Twente

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility scoring for obtaining blood flow measurements in the AAA Scoring of the obtained data will be performed by a group of 5 experts Through study completion, an average 6 months
Secondary Additional value of microbubble contrast injections on signal to noise ratio Measurements will be performed with and without contrast, added value on signal to noise ratio will be investigated. Through study completion, an average 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01942070 - A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction N/A
Active, not recruiting NCT05007535 - Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound
Recruiting NCT05307965 - RETRIEVE-AMI Study N/A
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Completed NCT01328691 - Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus N/A
Completed NCT00539045 - Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction N/A
Completed NCT01124942 - MGuard Stent in ST-elevation Myocardial Infarction N/A
Terminated NCT01147796 - Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus N/A
Not yet recruiting NCT05870449 - The Impact of Climate Environment in Different Latitudes on the Occurrence of PICC Complications N/A
Completed NCT01410539 - Mechanism Of Stent Thrombosis (MOST) Study Phase 4
Recruiting NCT05386342 - A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters N/A
Terminated NCT02945280 - Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis Phase 4
Completed NCT01281033 - CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Phase 4
Completed NCT04229433 - The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects Phase 1
Active, not recruiting NCT00914472 - Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure. Phase 3